🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Adds a touch of creativity to daily essentials. Get: niftyessence.com/holder

#ESCardioOncology2025 starts right now‼️ More than 70 countries sharing cardio-oncology knowledge. Let’s go‼️ European Society of Cardiology Teresa López Fdez

What’s the future needs for #CardioOncology trials? Perfectly summarized by @PennThalheimer at #ESCardioOnco2025🫀 📍Define mechanisms linking cancer & #CTRCD 📍Expand the field of #ReverseCardioOncology 📍Stratify individual patient risk 📍Enable precise phenotyping 📍more #AI

Great friends! Great memories #ESCardioOnco2025 International Cardio-Oncology Society European Society of Cardiology

Who is considered a cancer survivor? Dr. Susan Dent (Susan dent) leads our Judy DiMarzo Cancer Survivorship Program. She gives a definition and explains why this matters. Our Survivorship team is here to help! To learn more, call (585) 275-6956. #CancerSurvivorMonth

Mike Fradley, MD International Cardio-Oncology Society Susan dent Zsofia D. Drobni, MD, PhD Susan dent Mike Fradley, MD #ESCardioOnco2025 International Cardio-Oncology Society

If #cardiotoxicity occurs during #chemotherapy, should we stop the treatment?🫀 Presented by Dr Darryl Leong: ⚖️ Permissive cardiotoxicity balances effective #cancer therapy with #CVrisk management by: 📍Careful cardiac monitoring 📍Cardioprotective medications ➡️ ⚠️Limited

Dr Fradley stresses the importance of QT interval BUT we need to do a better job in measuring! ⁦International Cardio-Oncology Society⁩ ⁦European Society of Cardiology⁩

Great joint ICOS /ESC session at the inaugural ESC cardiology-oncology conference in Florence - how to establish a successful cardio-oncology program! ⁦International Cardio-Oncology Society⁩ ⁦European Society of Cardiology⁩

It was a privilege to participate in this panel discussion -how to establish a #cardiooncology program. Congratulations to Teresa Lopez Fernandez and #alexanderlyon on a great inaugural CO #ESC conference 👏🏼 OncoAlert Oncology Brothers #Oncology #Cardiology #MedTwitter Mike Fradley, MD

Representing ICOS (President Dent and President elect Fradley)at the inaugural ESC cardio-oncology meeting in Florence - working together to improve cardiovascular health of patients with cancer ⁦International Cardio-Oncology Society⁩ ⁦OncoAlert⁩ ⁦Oncology Brothers⁩ ⁦MASCC⁩

Thanks you #ESCardiOnco2025 for allowing to share our experience in cardioprotection. iLACO European Society of Cardiology International Cardio-Oncology Society ACORA Vanesa Gregorietti Teresa Lopez Fernandez Diego Costa

Happy to share #ESCardioOnco2025 with leaders in cardio-oncology and to represent International Cardio-Oncology Society iLACO and ACORA around the world. European Society of Cardiology Vanesa Gregorietti @sdent_cardioon Mike Fradley, MD

#GCOS25 Abstracts proposals are due in one week! Submit your proposal by July 2nd to share your research in 🇿🇦 South Africa. Submit here: form.jotform.com/250751427992565 #cardioonc #cardiooncology #cancerresearch #oncology

Happy to me one of the #mascc25 social media ambassadors! See you soon Seattle!

Congrats Kuan & team! GLP1RA have been associated with ⬇️ mortality in cancer pts & even ⬇️ progression of MGUS to MM, this study shows it can ⬇️adverse CV outcomes & all cause mortality in pts with MGUS & diabetes Michael Nanna @knowingalok #cardioonc

JCOG1017 trial found that primary tumor resection (PTR) did not prolong overall survival in de novo Stage IV breast cancer. However, it improved local control and might benefit subsets like premenopausal patients or those with single-organ metastasis. JCOGbreast Tadahiko Shien

📢🧵Two back-to-back papers highlight a critical and overlooked issue in HR+/HER2– metastatic breast cancer (mBC): ⚠️cardiovascular comorbidities & QTc-risk meds are the norm, not exception. Here’s what we found & why it matters for oncologists + cardiologists👇Susan dent

Exercise is medicine. Physically active breast cancer survivors had 31% (95% CI: 25–37%) reduction in risk of breast cancer mortality relative to physically inactive pts. pmc.ncbi.nlm.nih.gov/articles/PMC12…

Check out this recent paper on #InflammatoryBreastCancer, it examines the clinicogenomic characterization of #IBC. 👉pubmed.ncbi.nlm.nih.gov/40378057/ @npriedig Brittany Bychkovsky, MD jennifer bellon Tari King MD Eric Winer, MD Lynette Sholl Sara Tolaney Nancy Lin, MD Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Romualdo Barroso, MD PhD